Advertisement

ADVERTISEMENT

Health Economics and Outcomes Research

The Need for Continuous Cost-Effectiveness Analysis
Healthcare Economist
The Need for Continuous Cost-Effectiveness Analysis
07/06/2020
Jason Shafrin, PhD, highlights a study noting that value assessment is not a one-time endeavor but needs to be revisited as a treatment landscape evolves.
Jason Shafrin, PhD, highlights a study noting that value assessment is not a one-time endeavor but needs to be revisited as a treatment landscape evolves.
Jason Shafrin, PhD, highlights a...
07/06/2020
Journal of Clinical Pathways
News
Financial Hardship Associated With Increased ED Visits, Less Preventive Care
06/23/2020
A study from the American Cancer Society found higher medical and non-medical financial hardships are independently associated with more ED visits, lower receipt of some preventive services, and worse self-reported...
A study from the American Cancer Society found higher medical and non-medical financial hardships are independently associated with more ED visits, lower receipt of some preventive services, and worse self-reported...
A...
06/23/2020
Journal of Clinical Pathways
News
First Ever Oncology Hospital-At-Home Evaluation Shows Better Outcomes, Lower Costs
06/02/2020
The first ever reported trial of an adult oncology hospital-at-home program shows strong evidence for reduced hospitalizations, ED visits, and costs, according to a presentation at the American Society of Clinical...
The first ever reported trial of an adult oncology hospital-at-home program shows strong evidence for reduced hospitalizations, ED visits, and costs, according to a presentation at the American Society of Clinical...
The...
06/02/2020
Journal of Clinical Pathways
News
Provider Perceptions of Cost, Safety of Oral Oncolytic Agents
05/28/2020
A recent survey shed light on the perceptions of health care workers regarding the cost and safety of oral oncolytic agents, as well as highlighted perceptions of impact on patient care. Results of the survey were...
A recent survey shed light on the perceptions of health care workers regarding the cost and safety of oral oncolytic agents, as well as highlighted perceptions of impact on patient care. Results of the survey were...
A...
05/28/2020
Journal of Clinical Pathways
News
Cost-Benefit Analysis Shows Difference in Price, Clinical Benefit of Cancer Drugs in US, Europe
05/26/2020
A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...
A cost-benefit analysis published in The Lancet Oncology (May 2020;21[5]:664-670) compared the prices and clinical benefit of cancer drugs in the US vs Europe. Both the US and European countries are faced with the...
A...
05/26/2020
Journal of Clinical Pathways
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
Research Reports
The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis
05/19/2020
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
Abstract: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC...
...
05/19/2020
Journal of Clinical Pathways
Research in Review
Blood Flow Measurement Predicts Effectiveness of Ovarian Cancer Treatment
07/03/2017
JCP Editors
A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment, according to a recent study published in Clinical Cancer Research (June 2017;...
A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment, according to a recent study published in Clinical Cancer Research (June 2017;...
A tool...
07/03/2017
Journal of Clinical Pathways
Research in Review
Targeted Therapy Improves Survival in Older Patients With B-Cell Malignancy
06/27/2017
JCP Editors
A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...
A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...
A...
06/27/2017
Journal of Clinical Pathways
Viewpoint
The Current Cost of Cancer Drugs: Physician, Payer and Government Concerns Grow
10/27/2015
The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...
The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...
The...
10/27/2015
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

March 23 ⁠–⁠ March 24
April 27 ⁠–⁠ April 28
Great Debates & Updates in Diabetic Foot
November 30 ⁠–⁠ December 2
AIBD logo
November 27 ⁠–⁠ November 29
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
May 13 ⁠–⁠ May 14
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use